A 52-WEEK, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF TIDEGLUSIB FOR THE TREATMENT OF CONGENITAL DM1 (REACH CDM X)

Registry ID

AMO-02-MD-2-004

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

AMO PHARMA LTD

Start date

2023-11-23

Last update

2021-07-20

Conditions

• CONGENITAL MYOTONIC DYSTROPHY

Related clinical trials

• A PHASE 1/PHASE 2 OPEN-LABEL SINGLE ARM STUDY WITH DOSE ESCALATION (PART A), AND DOSE EXPANSION (PART B) PARTS TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SAR446268, AN ADENO-ASSOCIATED VIRAL VECTOR-MEDIATED GENE THERAPY IN PARTICIPANTS 10 TO 50 YEARS OLD WITH NON-CONGENITAL MYOTONIC DYSTROPHY TYPE 1

View on source registry